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p53 tumour-suppressor gene mutations are mainly localised on exon 7 in
human primary and metastatic prostate cancer
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Summary Mutations in the p53 tumour-suppressor gene are among the most common genetic alterations in
human cancers. In the present study we analysed the mutations in the p53 tumor-suppressor gene in 25 primary
and 20 metastatic human prostate cancer specimens. DNA extracted from the paraffin-embedded sections was
amplified by hot-start polymerase chain reaction, and p53 gene mutations in the conserved mid-region (exons
4-9) were examined using single-strand conformation polymorphism (SSCP) analysis and immunohistochem-
istry. In the present study, we used a novel hot-start PCR-SSCP technique using DNA Taq polymerase
antibody, which eliminates primer-dimers and non-specific products. Because of this new technique, the results
of PCR-SSCP showed very high resolution. Polymerase chain reaction products were sequenced directly for
point mutations for the p53 gene. Mutations were found in 2 out of 25 primary prostate cancers (8%) and 4
out of 20 metastatic cancers (20%). Mutations were observed exclusively in exon 7 and not in exons 4, 5, 6, 8
or 9. Nuclear accumulation ofp53 protein, determined by immunohistochemistry, correlated with the degree of
metastasis in prostatic cancer.
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Mutations in the p53 tumour-suppressor gene, located on
chromosome 17p13, are the most frequently observed
alterations in human cancer (Hollstein et al., 1991). The
p53 mutations can be in one of the four domains of the
protein: NH2-terminal transactivation domain, a central
DNA binding domain, an oligomerisation domain, and a
basic COOH-terminal nuclear localisation domain (Clore et
al., 1994). In this regard Harris and Hollstein (1993) have
reported that most p53 mutations found in human cancers
are located within the DNA-binding domain. The wild-type
p53 protein has a short half-life and cannot be detected by
immunohistochemical methods. However, mutated p53 has a
considerably expanded half-life and is detectable immunohis-
tochemically. Therefore, p53 staining in tissue sections is
indicative of mutant p53 protein.
Prostate cancer is the most common neoplasm in western
countries. Despite its high incidence, relatively few investiga-
tions have attempted to unravel the genetic alterations (e.g.
tumour-suppressor genes and oncogenes) that might play a
role in understanding the pathophysiology and regulation of
prostate cancer (Dinjens et al., 1994, Peehl, 1993, Carter
1990). The mechanisms responsible for p53 inactivation
include gene deletion, somatic and germline point muta-
tions, inactivation of proteins encoded by DNA tumour
viruses, such as the E6 protein of human papilloma viruses
and SV 40 large T antigen which bind to and neutralise the
function of p53 protein through various mechanisms (Malkin
et al., 1990; Mietz et al., 1992; Dutta et al., 1992). p53 can
also mediate transcriptional activation of genes containing at
least two copies of a 10 bp sequence motif that constitutes a
specific binding site for this protein (Vogelstein et al., 1992;
Kern et al., 1992; Scharer and Iggo, 1993). In some cases the
down-regulation may be via interactions of p53 with TATA-
binding factor involved in transcription initiation in genes
that contain a TATAA box (Mack et al., 1993). In a recent
study, Miyashita et al. (1994) have reported that p53 may
either directly or indirectly down-regulate the bcl-2 gene
which is involved in the regulation ofprogrammed cell death.
Based upon these studies, it is clear that p53 may play a
significant role in the regulation of various cancers. However,
p53 mutation sites are different in different cancers. In
prostate cancer, there is no controlled study which clearly
demonstrates the mutational hotspot in different p53 regions.
The present study was designed to characterise p53 mutations
in primary and secondary human prostate cancer specimens
using hot-start PCR-single-strand conformation polymorph-
ism (SSCP) analysis, sequencing of PCR product and
immunohistochemistry.
Materials and methods
Prostate cancer tissues
Formalin-fixed, paraffin-embedded surgical specimens of
primary and metastatic prostatic adenocarcinoma [radical
prostatectomy (32 specimens) and transurethral resections (13
specimens)] were retrospectively identified from the patholo-
gical files of the VA Medical Center, San Francisco,
California. Twenty-five primary prostate and 20 lymph node
metastases specimens were used in this study. Out of 25
primary prostate cancer specimens, ten showed grade 3
tumours, three showed grade one and twelve showed grade 2
tumours. Out of 20 metastatic prostate cancer tumours, five
had grade 3 tumours, six specimens had grade four and nine
had grade two tumours.
Procedure for conventional PCR
Paraffin-embedded prostate cancer specimens were used for
the extraction of DNA. About 5-6 gm sections from
prostatic carcinoma tissues were cut and stained with
haematoxylin and eosin. All sections were reviewed by a
pathologist. For this purpose the samples containing no
carcinoma were considered normal, and the presence of
carcinoma was confirmed histologically. Genomic DNA was
extracted and quantified from these tissues as described
earlier (Gao et al., 1995; Dahiya et al., 1995a). Genomic
DNA (10-100 ng) was added to 25 MIl of solution containing
10 mm Tris-HCl, pH 8.3, 50 mm potassium chloride, 1.5 mM
magnesium chloride, 0.01% gelatin, 0.1-1 gM each of
upstream and downstream primers (Table I), 0.2 mM dNTP
(deoxynucleoside triphosphates), 1 unit Taq DNA polymer-
ase. After heating to 94°C for 3 min, the mixture was
subjected to 30 cycles of denaturing (94°C for 30 s),
annealing (56-68°C for 30 s) and extension (72°C for 30 s).
After the last cycle the reaction was maintained at 72°C for
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10 min. The selection of annealing temperature, times,
primers' concentration and number of cycles for a PCR
reaction is very critical. These factors depend on the DNA
being amplified and the primers used for a particular PCR
reaction (Mullins and Faloona, 1987).
Procedure for hot-start PCR using DNA Taq polymerase
antibody
Before the reaction mixture first reaches high temperature,
non-specific hybridisation and primer-dimers have already
been formed owing to the low-level activity of Taq DNA
polymerase at room temperature. These non-specific
products can be amplified during the thermal cycling,
leading to lowered yield of the desired products and
multiple non-specific bands. To overcome this non-specific
amplification, Taq DNA polymerase and the antibody
against Taq DNA polymerase (TaqStart antibody, Clon-
tech, Palo Alto, CA, USA) were added to the complete PCR
reaction mixture, heated to 94°C and processed to thermal
cycling as described under conventional PCR section
(Dahiya et al., 1995a; Sharkey et al., 1994). When Taq
DNA polymerase is mixed with Taq polymerase antibody,
the non-specific products and primer-dimers are eliminated
because the activity of Taq DNA polymerase is blocked by
the antibody during assembly of the reaction mixture at
room temperature. When the PCR solution is heated to high
temperature (>70'C), the Taq DNA polymerase is released,
and only specific products are produced at high temperature
(Dahiya et al., 1995a).
Single-stranded conformation polymorphism (SSCP)
Genomic DNA was isolated from five consecutive 5 gim
sections and amplified by hot-start polymerase chain reaction
(using TaqStart antibody, Clontech). The reaction mixture
containing template, 1 pCi [a-32P]dCTP, and primers was
amplified by hot-start PCR (p53 exons 5-9 primers see Table
1), and the generated fragment was denatured and analysed
by 6% polyacrylamide gel electrophoresis at room tempera-
ture. The separated DNA strands were visualised by
autoradiography and abnormally migrating SSCP bands
were observed.
Sequencing
The hot-start PCR-generated fragments of exon 7 of the p53
gene for wild-type and prostate cancer (C3) were denatured
and sequenced using the Sequenase version 2.0 DNA
sequencing kit (US Biochemical, Cleveland, OH, USA) and
[35S]dATP (Amersham, Arlington Heights, IL, USA) and p53
primers (see Table I). Genomic DNA from control samples
containing wild-type p53 alleles was sequenced in parallel
when confirming mutations in samples that were positive for
p53 in the PCR-SSCP analysis.
Immunohistochemistry
Paraffin-embedded sections (5 pm) of prostatic specimens
were deparaffinised in 10 mM citric acid, pH 6 and
microwaved for 10 min. The primary antibody [mouse anti-
human p53, clone DO-7 (DAKO Corp., Carpinteria, CA,
USA)] was diluted 1:100 in blocking solution [(5% goat
serum in phosphate-buffered saline (PBS)] and the sections
incubated for 1 h at room temperature. The sections were
rinsed in PBS-Tween 20 (0.1%), 4 x 15 min. The secondary
antibody (biotinylated anti-mouse IgG, Amersham) was
diluted 1:200 in blocking solution and incubated for 1 h at
room temperature. The sections were rinsed as before and
treated with ABC solution (Vector, Burlingame, CA, USA)
for 30 min followed by three 5 min PBS washes. Staining was
visualised after a 5 min incubation in 0.05% DAB, 0.15%
hydrogen peroxide, 0.18% cobalt chloride in PBS. Sections
were counterstained in haematoxylin and eosin (Dahiya et al.,
1989, 1992, 1995b).
Results and discussion
In the present study, we have examined 25 primary and 20
metastatic human prostate cancer specimens for p53
mutations by hot-start PCR-SSCP analysis, followed by
sequencing of the exon fragment with abnormally migrating
SSCP bands. We also examined the p53 protein expression by
immunohistochemistry using PAb 1801, which detects both
wild-type and mutated p53. The results of these experiments
are discussed below.
The sequences ofp53 primers used for PCR in this present
300 bp
200 bp
100 bp-
Figure 1 Hot-start PCR using p53 exon 6 primers in human
prostatic cancer. Genomic DNA (100 g) was amplified by hot-
start PCR using TaqStart antibody and exon 6 primers. The
products were separated on a 2% agarose gel and the product size
was 166bp for p53 exon 6 primers.
-166 bp
Table I Sequences of p53 primers used for PCR
Exon 5'-3' sequence PCR product
4 Sense TGC ACC AGC AGC TCC TAC AC 181 bp
4 Antisense CAT GGA AGC CAG CCC CTC AG
5 Sense GTG CCC TGA CTT TCA ACT CTG 266 bp
5 Antisense GGG CAA CCA GCC CTG TCG
6 Sense CGT CTA GAA TTC CTC ACT GAT TGC TC 166 bp
6 Antisense CGG TCG ACA GTT GCA AAC CAG A
7 Sense CGT CTA GAG GCC TGT GTT GTC TCC 165 bp
7 Antisense CGG TCG ACG GTG GCA AGT GGC TCC
8 Sense ATT ATC TTA CTG CCT CTT GCT TC 218 bp
8 Antisense CTT GGT CTC CTC CAC CGC
9 Sense GCC TCA GAT TCA CTT TTA TCA CC 161 bp
9 Antisense GAC TGG AAA CTT TCC ACT TGA TAA Gp53 gene mutations in prostate cancer
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study are shown in Table I. Figure 1 shows hot-start PCR
using exon 6 primers in human prostatic cancer. Using this
new technique, there was no non-specific product and the
bands are highly specific without any contamination. The
hot-start PCR-SSCP analysis of prostate cancer DNA for
exons 4, 5 and 6 of the p53 gene is shown in Figures 2, 3 and
4, respectively. All the bands show a similar pattern
suggesting the absence of p53 mutation in exons 4, 5 and 6
of the p53 gene. The resolution of the bands is very clear
because of the new hot-start PCR-SSCP technique. In a
recent study we have compared the 'hot-start' SSCP method
with 'non-hot-start' and found that hot-start SSCP is a far
Exon 4
1 2 3 4 5 6
superior technique than the regular SSCP (Dahiya et al.,
1995b). The exclusion of PCR contamination in prostate
cancer samples was checked by using DNA negative controls.
Figure 5 shows the PCR-SSCP analysis of p53 exon 7
from prostate cancer DNA. Lanes 5 and 6 show highly
distinct migrating bands in SSCP analysis, suggesting the
presence of mutation in these samples. Lanes 1, 2, 3, 4 and 7
did not show any mutation. There were 8% mutations ofp53
exon 7 in primary prostate cancer (2 out of 25 samples) and
20% mutations in lymph node metastatic prostate cancer (4
out of 20 samples). There was no mutation in p53 exons 8
and 9 in prostate cancer DNA. The results of these
experiments suggest that p53 mutations were exclusively in
exon 7 and not in exons 4, 5, 6, 8 or 9. Prior studies (Dinjens
et al., 1994; Navone et al., 1993) have shown that p53
mutations are also present in other exons such as 5, 6 and 8.
This discrepancy in results may be due to two main reasons:
(1) the technique used by previous authors does not clearly
show the shift in SSCP bands because of lack of hot-start
1 2 3 4 5
Exon 6
Figure 2 Hot-start PCR-SSCP analysis ofprostate cancer tissue
for exon 4 of the p53 gene. Genomic DNA (100jug) was amplified
by hot-start PCR using p53 exon 4 primers, denatured by heating
and separated on a 6% polyacrylamide gel. Lanes 1-6 represent
denatured products from different prostate cancer tissues. There
was no shift in band suggesting no mutation in p53 gene at exon
4.
Figure 4 Autoradiogram of SSCP analysis of prostate cancer
specimens for exon 6 of the p53 gene. Lanes 1 -5 show denatured
products of hot-start SSCP reaction analysed on 6% polyacry-
lamide gel. There was no mutation observed in exon 6 of p53
gene.
1 2 3 4 5 6 7
Figure 3 Autoradiogram of SSCP analysis of prostate cancer
specimens for exon 5 of the p53 gene. Lanes 1-5 show denatured
products of hot-start SSCP reaction analysed on 6% polyacry-
lamide gel. There was no mutation observed in exon 5 of p53
gene.
Exon 7
Figure 5 Autoradiogram of SSCP analysis of prostate cancer
specimens for exon 7 of the p53 gene. Lanes 1-7 show denatured
products of hot-start SSCP reaction analysed on 6% polyacry-
lamide gel. The shifted bands in lanes 5 and 6 (arrow) show the
mutation at exon 7 ofthe p53 gene. The shift in band is very clear
because of our new hot-start SSCP technique.p53 gene mutations in prostate cancer
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Figure 6 p53 gene mutation site in the prostate cancer tissues.
Hot-start PCR-generated fragments of exon 7 of p53 gene from
wild-type and prostate cancer tissues were denatured and
sequenced using the Sequenase kit. (a) The sequencing (antisense
direction) of the wild-type sample. (b) The prostate cancer DNA
sequencing with mutation of p53 exon 7 at codon 251 ATC
(isoleucine) AGC (serine).
PCR-SSCP technique, which is a much more specific and
reliable method; (2) based on the number of samples analysed
in this study, p53 mutations were found only in exon 7, but if
more samples were to be analysed then we may detect
mutations in other exons.
The biological function of p53 is not yet completely
understood, but the recent data indicate that p53 is a
transcriptional factor, which plays an important role in cell
cycle control and apoptosis. Wild-type p53 has been shown
to inhibit transformation by activated oncogenes in cell
culture, can inhibit growth of tumour cells in vitro and can
prevent tumour formation in animal models (Finlay et al.,
1989; Eliyahu et al., 1989; Baker et al., 1990; Chen et al.,
1990). Furthermore, transgenetic mice lacking p53 are prone
to the spontaneous development of tumours at a very early
stage, suggesting a significant role of p53 in preventing cancer
(Donehower et al., 1992). Prior studies (Xiong et al., 1993;
Dulic et al., 1994) have shown that p53 protein is believed to
exert its tumour-suppressor activity by stimulating the
transcription of the p21 gene product that in turn inhibits
cyclin-dependent kinase 4, thereby blocking cell division. p53
mutations may therefore constitute one of the few oncogenic
alterations that increase rather than decrease the sensitivity of
cells to anti-tumour agents (Vogelstein and Kinzler, 1992).
Figure 6 shows the p53 gene mutation site in the prostate
cancer tissues. Hot-start PCR-generated fragments of exon 7
of p53 gene from wild-type and prostate cancer tissues were
denatured and sequenced using the Sequenase kit. Figure 6a
shows the sequencing (antisense direction) of the wild-type
sample and figure 6b shows the prostate cancer DNA
sequencing with mutation of p53 exon 7 at codon 251 ATC
(isoleucine) -+ AGC (serine). In this regard several
investigators (Dinjens et al., 1994; Navone et al., 1993) have
suggested the presence of other mutational hotspots in
prostate cancer such as mutation in codon 232 (ATC -+
AAC); 273 (CGT -+ CAT); 248 (CGG -+ TGG); 179 (CAT
CGT) of the p53 gene. In the present study all six samples
were analysed and confirmed for point mutation using
sequencing gel. We observed mutation only in exon 7 of
the p53 gene; the number of hotspot mutations were limited
only to codons 232 (ATC
-. AAC) (two samples) and 251
Figure 7 Immunohistochemical staining of p53 in prostate
cancer tissue using PAb 1801, which detects both wild-type and
mutated p53 protein. p53 nuclear staining was observed in more
than 40% of the metastatic prostate cancer cells in each specimen.
(ATC -+ AGC) (six samples). Isaacs et al. (1991) reported
p53 mutations in three out of five prostate cancer cell lines
and one primary tumour. Mutations were at codons 126
(TSU cell line), 138 (PC-3 cell line) and 223 / 274 (DU-145
cell line) and at codon 197 in the primary tumour.
Introduction of wild-type p53 into the DU-145 cells induced
decreased growth of the tumour, suggesting a functional role
of mutated p53 in DU-145 prostate cancer cells. A large
number of human p53 mutants have been described with the
majority occurring as missense changes in one of the four
'hotspots' (amino acids 129-146, 171 - 179, 234-260 and
270-287) (Vogelstein and Kinzler, 1992). Representative
mutants from each of these four regions have been tested
for binding to p53-binding sites in vitro and for activation of
p53-binding site reporter gene expression in vivo and in vitro.
In the present study we found p53 mutation at codon 251
(exon 7) which is one of the four hotspots reported by
Vogelstein and Kinzler (1992). These authors further reported
that all mutants lose their ability to bind p53-binding sites
and accordingly cannot activate the expression of adjacent
reporter genes.
Figure 7 shows the immunohistochemical staining of p53
in prostate cancer tissue using PAb 1801, which detects both
wild-type and mutated p53 protein. All the specimens were
stained with PAb 1801 antibody and compared to determine
whether immunohistochemistry reliably detects overexpres-
sion of p53 as a result of mutation. All six specimens with
p53 mutations showed nuclear staining in more than 40% of
the metastatic prostate cancer cells in each specimen. Our
immunohistochemical data confirm and extend the findings
of other investigators (Thompson et al., 1992; Visakorpi et
al., 1992; Dinjens et al., 1994). However, Van Veldhuizen et
al. (1993) showed increased cytoplasmic p53 staining in more
than 79% of prostate cancer tissues but this study did not
confirm mutations by structural analysis of the p53 gene.
Taken together, these experiments suggest that the p53 gene
mutations are a late event in the progression of prostatic
cancer and are associated with metastatic stage, loss of
differentiation and transition from androgen-dependent to
androgen-independent growth.
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